Latest News and Press Releases
Want to stay updated on the latest news?
- 
                            
Dapirolizumab pegol (DZP) Phase 3 study presentations in SLE to show efficacy results across multiple clinical endpoints, including low disease activity/remission, flares, fatigue, joint pain and...
 - 
                            
EXTON, PA, Jan. 08, 2025 (GLOBE NEWSWIRE) -- At the 2024 American College of Rheumatology (ACR) Convergence, the organization unveiled updated guidelines for the screening, treatment, and management...
 - 
                            
Dapirolizumab pegol (DZP) met its primary endpoint, demonstrating statistically and clinically significant improvement across all organ systems as measured by BICLA, an endpoint measuring disease...